PD-L1 Expression in Squamous Cervical Carcinomas of Mozambican Women Living with or Without HIV

Overview

Journal Sci Rep

Specialty Science

Date 2024 Jun 5

PMID 38839923

Authors

Lucilia Lovane

Satish Tulsidas

Carla Carrilho

Christina Karlsson

Affiliations

Soon will be listed here.

Abstract

Programmed death-ligand 1 (PD-L1) is overexpressed in squamous cervical cancer (SCC) and can be used for targeted immunotherapy. The highest mortality rates of SCC are reported in sub-Saharan Africa, where Human immunodeficiency virus (HIV) prevalence is high. In Mozambique most SCC patients present at advanced stages. Thus, there is a need to introduce new treatment options. However, immunocompromised patients were frequently excluded in previous clinical trials. Our aim was to determine if PD-L1 expression in SCC is as prevalent among women living with HIV (WLWH) as among other patients. 575 SCC from Maputo Central Hospital were included. HIV status was available in 266 (46%) cases PD-L1 expression was scored through tumour proportion score (TPS) and combined positive score (CPS). PD-L1 was positive in 20.1% of the cases (n = 110), TPS (score ≥ 25%) and in 26.3% (n = 144), CPS (score ≥ 1). Stratifying according to the HIV status, WLWH were TPS positive in 16.7%, compared to 20.9%, p = 0.43, and concerning CPS 21.1% versus 28.7%, p = 0.19, respectively. PD-L1 status was not influenced by stage, Ki-67 or p16, CD8 expression influenced only CPS status. Our data indicates that the documented effect of PD-L1 therapy on SCC should be confirmed in randomized clinical trials in an HIV endemic milieu.

References

Okoye J, Ofodile C, Adeleke O, Obioma O . Prevalence of high-risk HPV genotypes in sub-Saharan Africa according to HIV status: a 20-year systematic review. Epidemiol Health. 2021; 43:e2021039. PMC: 8510839. DOI: 10.4178/epih.e2021039. View

Wherry E . T cell exhaustion. Nat Immunol. 2011; 12(6):492-9. DOI: 10.1038/ni.2035. View

Mezache L, Paniccia B, Nyinawabera A, Nuovo G . Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers. Mod Pathol. 2015; 28(12):1594-602. DOI: 10.1038/modpathol.2015.108. View

Zajac M, Boothman A, Ben Y, Gupta A, Jin X, Mistry A . Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma. Arch Pathol Lab Med. 2018; 143(6):722-731. DOI: 10.5858/arpa.2017-0555-OA. View

Cook M, Kim C . Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer: A Systematic Review. JAMA Oncol. 2019; 5(7):1049-1054. DOI: 10.1001/jamaoncol.2018.6737. View

Gong J, Chehrazi-Raffle A, Reddi S, Salgia R . Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018; 6(1):8. PMC: 5778665. DOI: 10.1186/s40425-018-0316-z. View

Williams G, Nicholson A, Snead D, Thunnissen E, Lantuejoul S, Cane P . Interobserver Reliability of Programmed Cell Death Ligand-1 Scoring Using the VENTANA PD-L1 (SP263) Assay in NSCLC. J Thorac Oncol. 2019; 15(4):550-555. DOI: 10.1016/j.jtho.2019.11.010. View

Feng M, Xu L, He Y, Sun L, Zhang Y, Wang W . Clinical significance of PD-L1 (CD274) enhanced expression in cervical squamous cell carcinoma. Int J Clin Exp Pathol. 2020; 11(11):5370-5378. PMC: 6963033. View

Lantuejoul S, Sound-Tsao M, Cooper W, Girard N, Hirsch F, Roden A . PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. J Thorac Oncol. 2019; 15(4):499-519. DOI: 10.1016/j.jtho.2019.12.107. View

10.

Puronen C, Ford E, Uldrick T . Immunotherapy in People With HIV and Cancer. Front Immunol. 2019; 10:2060. PMC: 6722204. DOI: 10.3389/fimmu.2019.02060. View

11.

Sherer M, Kotha N, Williamson C, Mayadev J . Advances in immunotherapy for cervical cancer: recent developments and future directions. Int J Gynecol Cancer. 2022; 32(3):281-287. DOI: 10.1136/ijgc-2021-002492. View

12.

Enwere E, Kornaga E, Dean M, Koulis T, Phan T, Kalantarian M . Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. Mod Pathol. 2017; 30(4):577-586. DOI: 10.1038/modpathol.2016.221. View

13.

Stewart T, Moodley J, Walter F . Population risk factors for late-stage presentation of cervical cancer in sub-Saharan Africa. Cancer Epidemiol. 2018; 53:81-92. DOI: 10.1016/j.canep.2018.01.014. View

14.

El Zarif T, Nassar A, Adib E, Fitzgerald B, Huang J, Mouhieddine T . Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium. J Clin Oncol. 2023; 41(21):3712-3723. PMC: 10351941. DOI: 10.1200/JCO.22.02459. View

15.

Jedy-Agba E, Joko W, Liu B, Buziba N, Borok M, Korir A . Trends in cervical cancer incidence in sub-Saharan Africa. Br J Cancer. 2020; 123(1):148-154. PMC: 7341858. DOI: 10.1038/s41416-020-0831-9. View

16.

Rasmussen T, Rajdev L, Rhodes A, Dantanarayana A, Tennakoon S, Chea S . Impact of Anti-PD-1 and Anti-CTLA-4 on the Human Immunodeficiency Virus (HIV) Reservoir in People Living With HIV With Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study. Clin Infect Dis. 2021; 73(7):e1973-e1981. PMC: 8492152. DOI: 10.1093/cid/ciaa1530. View

17.

Park Y, Koh J, Na H, Kwak Y, Lee K, Ahn S . PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs. Cancer Res Treat. 2020; 52(3):661-670. PMC: 7373862. DOI: 10.4143/crt.2019.718. View

18.

Boothe M, Sathane I, Sema Baltazar C, Chicuecue N, Horth R, Fazito E . Low engagement in HIV services and progress through the treatment cascade among key populations living with HIV in Mozambique: alarming gaps in knowledge of status. BMC Public Health. 2021; 21(1):146. PMC: 7811257. DOI: 10.1186/s12889-020-10039-2. View

19.

Loharamtaweethong K, Puripat N, Praditphol N, Thammasiri J, Tangitgamol S . PD-L1 protein expression and copy number gains in HIV-positive locally advanced cervical cancer. Ther Adv Med Oncol. 2020; 12:1758835920963001. PMC: 7580136. DOI: 10.1177/1758835920963001. View

20.

Vora K, Ricciuti B, Awad M . Exclusion of patients living with HIV from cancer immune checkpoint inhibitor trials. Sci Rep. 2021; 11(1):6637. PMC: 7988004. DOI: 10.1038/s41598-021-86081-w. View